GLP-1 receptor agonists and hospitalization due to infections in patients with type 2 diabetes: A nationwide cohort study
Authors' conclusion
Our study demonstrates that GLP-1RA administration offers advantages over DPP4is in reducing the incidence of severe lower respiratory tract infections and diabetic foot infections requiring hospitalization in individuals with type 2 diabetes.
Study context
- Population
- Patients with T2D, Taiwan National Health Insurance data, 2016–2021matched cohort
- Participants
- 17,706 vs 17,706
- Exposure
- GLP-1 RA vs DPP-4i initiation
- GLP-1RAn = 17,706
- DPP4in = 17,706reference
- Outcome
- Hospitalizations due to various infections
Methodological detailsnationwide, 1:1 propensity score-matched
- Nationwide
- 1:1 propensity score-matched
Main finding
As reported in the abstract
Hospitalization due to infections
Each group vs DPP4iEstimate (95% CI)
GLP-1RA
aHR, lower respiratory tract infections 0.56(0.49–0.65)
GLP-1RA
aHR, diabetic foot infections 0.77(0.65–0.91)
GLP-1RA
aHR, intraabdominal infections 0.91(0.73–1.13)
GLP-1RA
aHR, reproductive and urinary tract infections 0.98(0.75–1.27)
Observational data: associations, not effects.
Original publication
GLP-1 receptor agonists and hospitalization due to infections in patients with type 2 diabetes: A nationwide cohort study. Diabetes Res Clin Pract. Published 10 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →